Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.4
Summary of Significant Accounting Policies - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 22, 2021
USD ($)
$ / shares
shares
Oct. 21, 2021
shares
Dec. 31, 2022
USD ($)
Nov. 30, 2022
USD ($)
plan
$ / shares
shares
Nov. 30, 2021
USD ($)
Aug. 31, 2022
USD ($)
$ / shares
shares
Aug. 31, 2020
segment
Oct. 19, 2021
shares
Sep. 01, 2021
USD ($)
Aug. 31, 2021
USD ($)
Concentration Risk [Line Items]                    
Contract with customer, term       12 months            
Contract with customer, cancellation period       30 days            
Unbilled accounts receivable       $ 2,706,000   $ 2,105,000        
Number of reportable segments | segment             1      
Cash, uninsured amount       463,000   615,000        
Capitalized computer software, additions       0 $ 0          
Research and development expense       2,200,000 700,000          
Operating lease, liability       4,157,000            
Workers' compensation, claim responsibility per occurrence       500,000            
Workers' compensation asset, current       0   0        
Workers' compensation asset, noncurrent       0   0        
Workers' compensation liability, current       575,000   567,000        
Workers' compensation liability, noncurrent       1,196,000   $ 1,227,000        
Disposal group, including discontinued operation, workers' compensation liability, current       1,400,000            
Disposal group, including discontinued operation, workers' compensation liability, noncurrent       3,400,000            
Disposal group, including discontinued operation, workers' compensation asset, current       0            
Disposal group, including discontinued operation, workers' compensation asset, noncurrent       0            
Advertising expense       $ 700,000 1,400,000          
Number of stock-based compensation plans | plan       1            
Exercise price of warrants (in dollars per share) | $ / shares       $ 34.78   $ 47.99        
Class of warrant or right, outstanding (in shares) | shares       1,252,748   522,786        
Common stock, shares, transferred (in shares) | shares   15,000                
Financial instruments subject to mandatory redemption, settlement terms, share value, amount, current       $ 117,770,000   $ 116,969,000        
Increase in Marketable securities in trust account and Class A mandatory redeemable common shares $ 13,000,000       13,270,000          
Deferred offering costs – SPACs (See Note 5)       0           $ 48,261,000
Payments of stock issuance costs       $ 0 $ 3,502,000          
IHC                    
Concentration Risk [Line Items]                    
Deferred offering costs – SPACs (See Note 5) $ 9,500,000                 $ 9,800,000
Accounting Standards Update 2018-11                    
Concentration Risk [Line Items]                    
Operating lease, liability                 $ 7,700,000  
IHC                    
Concentration Risk [Line Items]                    
Variable interest entity, qualitative or quantitative information, ownership percentage       15.00%            
Common stock, shares, owned (in shares) | shares 2,110,000 2,125,000   2,110,000            
Increase in Marketable securities in trust account and Class A mandatory redeemable common shares $ 9,500,000                  
Payments of stock issuance costs 3,500,000         $ 3,500,000        
IPO | Subsequent Event                    
Concentration Risk [Line Items]                    
Redemption funds distributed to shareholders     $ 117,574,000              
IPO | IHC                    
Concentration Risk [Line Items]                    
Sale of stock, number of shares issued in transaction (in shares) | shares           11,500,000        
Proceeds from initial public offering of IHC 115,000,000                  
Assets held-in-trust $ 1,725,000     $ 1,700,000            
Sale of stock, price per share (in dollars per share) | $ / shares $ 10.00                  
Sale of stock, number of common shares issued per unit (in shares) | shares 1             1    
Sale of stock, number of warrants issued per unit (in shares) | shares 1                  
Class of warrant or right, number of securities called by each warrant or right (in shares) | shares 1             1    
Exercise price of warrants (in dollars per share) | $ / shares $ 11.50                  
Initial business combination consummation period 12 months                  
Redemption percentage 100.00%                  
IPO | IHC | Placement Warrants                    
Concentration Risk [Line Items]                    
Exercise price of warrants (in dollars per share) | $ / shares $ 11.50                  
Class of warrant or right, outstanding (in shares) | shares 4,639,102                  
Sale of warrants, price per share (in dollars per share) | $ / shares $ 1.00                  
Aggregate purchase price $ 4,639,102                  
Minimum                    
Concentration Risk [Line Items]                    
Capitalized software development, useful life       3 years            
Minimum | Software Development                    
Concentration Risk [Line Items]                    
Property, plant and equipment, useful life       3 years            
Maximum                    
Concentration Risk [Line Items]                    
Capitalized software development, useful life       5 years            
Maximum | Software Development                    
Concentration Risk [Line Items]                    
Property, plant and equipment, useful life       5 years            
Seven Clients | Customer Concentration Risk | Accounts Receivable                    
Concentration Risk [Line Items]                    
Concentration risk, percentage       88.00%            
Three Clients | Customer Concentration Risk | Accounts Receivable                    
Concentration Risk [Line Items]                    
Concentration risk, percentage         98.00%